Roger Jeffs retired as President and co-CEO at United Therapeutics in 2016 after a successful 18-year tenure. Dr. Jeffs joined United Therapeutics Corporation during its start-up phase in 1998 as Director of Research, Development, and Medical, and served as the company’s President and Chief Operating Officer from 2001 to 2014 and President & co-CEO from 2015-2016. While at United Therapeutics, Dr. Jeffs helped lead the IPO, oversaw the clinical development and regulatory approval of six products for rare diseases, and managed the commercial effort that led to >20% CAGR and $1.5B annual revenue run rate. United Therapeutics was consistently recognized as one of the fastest growing companies and best places to work during his tenure. Dr. Jeffs received the 2015 Wings of Hope Award from the Solving Kids’ Cancer organization in “recognition of his visionary leadership in advancing cancer research while prioritizing the lives of children”. Dr. Jeffs previously held positions at Amgen, Inc. and Burroughs Wellcome Co where he held roles in clinical development. Dr. Jeffs holds an undergraduate degree in chemistry from Duke University and a Ph.D. in pharmacology from the University of North Carolina School of Medicine. Dr. Jeffs previously served on the Board of Directors for United Therapeutics, Dova Pharmaceuticals, Sangamo Therapeutics and Albireo Pharma and currently serves on the Board of Axsome Therapeutics.
Mr. Kaseta joined Liquidia in December 2020 with an extensive background in corporate finance, business strategy and the commercialization of biopharma products. Prior to Liquidia, Mr. Kaseta served as the Chief Financial Officer at Aerami Therapeutics, a private biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension (PAH). Previously, Mr. Kaseta served as the Chief Financial Officer at Aralez Pharmaceuticals Inc. (Nasdaq: ARLZ) and spent eleven years at Sanofi in a variety of financial roles, culminating in the Chief Financial Officer at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. In this role he managed a $10 billion business covering several product launches and over one hundred products across eight therapeutic areas. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.
Mr. Lippe is responsible for all aspects of operations at Liquidia, including manufacturing, supply chain management, quality, facilities, and program management. Prior to joining Liquidia in 2015, Mr. Lippe served as an Executive Vice President of Operations and Chief Operations Officer at Alexza Pharmaceuticals. In these roles, he had operational oversight for the scale-up and optimization of supply that supported the launch of the company’s first commercial product, and he advanced a platform proof-of-concept which accelerated the company’s product pipeline. He also worked as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., and as the Head of Manufacturing for one of Genentech’s Vacaville operating facilities. Mr. Lippe spent 10 years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. He received his MPH and MBA degrees from the University of California, Berkeley, and received a B.S. degree in Marine Engineering from the United States Coast Guard Academy.
Mr. Moomaw joined Liquidia in November 2020 from RareGen where he held the position of Chief Operations Officer (COO) since August 2018. Mr. Moomaw is a seasoned leader in biopharmaceuticals with extensive experience launching products and developing commercial strategies and sales organizations. At RareGen he co-founded the company, built the organization, and launched Treprostinil for PAH. Prior to RareGen Mr. Moomaw was Vice President of Marketing at Opko Health. As Vice President of Marketing for United Therapeutics he had responsibility for Remodulin (parenteral Treprostinil), Tyvaso (inhaled Treprostinil), and Orenitram (oral Treprostinil) for PAH. Mr. Moomaw also held a variety of sales and marketing roles of increasing responsibility at Eli Lilly for over ten years. Mr. Moomaw holds his MBA from the University of Michigan and a Bachelor of Science (B.S.) from Miami University.
As Senior Vice President, Corporate Development & Strategy at Liquidia, Mr. Adair is responsible for pursuing collaboration and licensing opportunities for the company. Prior to joining Liquidia in 2016, Mr. Adair led business development efforts at BioCryst Pharmaceuticals as their Executive Director of Corporate Development. His work included the commercial launch and subsequent partnering of the company’s first FDA approved drug. He also worked at MedImmune/AstraZeneca in roles of increasing responsibility in business development, marketing and operations. Before entering the pharmaceutical industry, Mr. Adair worked as an analytical chemist for Syngenta and served as an officer in the United States Army. He received an MBA from the Tuck School of Business at Dartmouth College and a B.S. in Chemistry from Wake Forest University.